Relapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents

Please Log In or Register to continue.

Release Date: October 19, 2016
Expiration Date: October 19, 2017

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The multitude of novel agents and new drug regimens approved in relapsed/refractory multiple myeloma (RRMM) has made a major impact on treatment paradigms and clinical practice recommendations. In this activity, Dr. Adam D. Cohen, the Director of Myeloma Immunotherapy and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, will describe the current standard of care in RRMM, taking into account new therapies and updates to disease management guidelines, as well as future outlooks on the treatment landscape.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in new drug regimens for multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline the current treatment paradigms in relapsed/refractory multiple myeloma (RRMM)
  • Explain the advantages and disadvantages of the current standard of care in RRMM
  • Describe the future outlook on the standard of care in RRMM

Agenda

Relapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents – Adam D. Cohen, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 19, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Adam D. Cohen, MD
Director, Myeloma Immunotherapy
Assistant Professor, Hematology/Oncology Division
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania

Dr. Adam Cohen received his medical degree from the University of Pennsylvania, Philadelphia, where he also completed an internal medicine residency. He then completed a hematology/oncology fellowship, and was a research associate in the Laboratory of Tumor Immunology at Memorial Sloan-Kettering Cancer Center, New York. Dr. Cohen is currently Director of Myeloma Immunotherapy and Assistant Professor of Hematology/Oncology at Abramson Cancer Center of the University of Pennsylvania.

Dr. Cohen is board certified in internal medicine, medical oncology, and hematology. He is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and the American Society of Hematology. He is also a member of the Multiple Myeloma Committee, Eastern Cooperative Oncology Group, and has served on the Multiple Myeloma Panel, National Comprehensive Cancer Network. In addition, Dr. Cohen is an ad hoc reviewer for several journals, including Leukemia, Blood, Amyloid, and Clinical Cancer Research. He has co-authored over 50 original articles, book chapters, and reviews on DNA vaccines, tumor immunity, multiple myeloma, amyloidosis, and stem cell transplant.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-112-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Adam Cohen has received honoraria related to formal advisory activities from Bristol-Myers Squibb Company and Janssen Pharmaceuticals, Inc. He has received grant support related to research activities from Bristol-Myers Squibb.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Physician Payments, Sunshine Act

MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.